Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth
01:40pm, Tuesday, 08'th Aug 2023
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.
Markets Plunge at Midday After Bank Downgrades
01:25pm, Tuesday, 08'th Aug 2023
U.S. equities sank at midday on Tuesday, Aug. 8, 2023, following bank downgrades by Moody's and data showing credit card debt rose to a record.
Eli Lilly Beats Estimates and Boosts Its Guidance as Diabetes Drug Sales Soar
12:40pm, Tuesday, 08'th Aug 2023
Eli Lilly shares rose to a record after the company posted better-than-expected results and raised its guidance on soaring demand soared for its diabetes drug, Mounjaro.
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
12:10pm, Tuesday, 08'th Aug 2023
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wa
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
11:45am, Tuesday, 08'th Aug 2023
Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.
UPS cuts outlook, Moody's downgrades U.S. banks, Eli Lilly raises guidance: Aug 8, 2023
11:04am, Tuesday, 08'th Aug 2023
Yahoo Finance anchor Julie Hyman breaks down three things to know for August 8, 2023 including UPS earnings, Moody's downgrading U.S. banks, and Eli Lilly raising guidance.
Call Traders Blast Ely Lilly Stock Amid Post-Earnings Peak
10:15am, Tuesday, 08'th Aug 2023
The shares of Eli Lilly And Co (NYSE:LLY) are trading at record highs today, last seen up 16% at $522.45, following a blockbuster trip to the earnings confessional.
Eli Lilly (LLY) Q2 Earnings and Revenues Top Estimates
09:10am, Tuesday, 08'th Aug 2023
Eli Lilly (LLY) came out with quarterly earnings of $2.11 per share, beating the Zacks Consensus Estimate of $1.98 per share. This compares to earnings of $1.25 per share a year ago.
Wegovy's success in reducing cardio risk is ‘an important win,' and a ‘best-case scenario,' say Wolfe analysts
08:02am, Tuesday, 08'th Aug 2023
The success of Novo Nordisk's NVO, +3.04% NOVO.B, +13.49% Wegovy in reducing cardiovascular events in obese adults is an important win for the obesity category with positive implications for that comp
Dow seen lower as Moody's hits banks but Eli Lilly set to fly
07:56am, Tuesday, 08'th Aug 2023
7.50am: Banks hit by Moody's downgrades, Eli Lilly ups guidance US stocks are expected to open lower with banks under pressure after Moody's downgraded ratings for a number of small to mid-sized lende
Eli Lilly stock up in premarket as Mounjaro diabetes drug sales surge
07:46am, Tuesday, 08'th Aug 2023
Eli Lilly and Co (NYSE:LLY) stock is seen higher ahead of Tuesday's open after reporting a strong, expectation-beating, second-quarter performance led by type-2 diabetes drug Mounjaro. Revenue for the
Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
07:04am, Tuesday, 08'th Aug 2023
Eli Lilly's stock has been on a tear, driven by positive trial results for its Alzheimer's drug and progress with its promising obesity drug pipeline.
Eli Lilly beats profit estimates on strength of new diabetes drug
06:51am, Tuesday, 08'th Aug 2023
Eli Lilly beat Wall Street estimates for second-quarter profit on Tuesday, buoyed by strong demand for its new diabetes drugs Mounjaro, ahead of a decision on the medicine's use as a weight-loss treat
Indices Fight Back; PLTR Meets, SWKS and PARA Beat
07:39pm, Monday, 07'th Aug 2023
The Dow climbed back +408 points on the day, +1.16%, while the Nasdaq gained +84 points, +0.61%.
People are 'scratching and clawing' for negative narrative around obesity drugs: Mizuho's Jared Holz
06:42pm, Monday, 07'th Aug 2023
Jared Holz, Mizuho healthcare sector specialist, joins 'Fast Money' to talk Eli Lilly earnings, obesity drug demand and more.
